What is Proton Therapy

Call Now For More Information

General Questions or
Schedule an Appointment

1-855-528-7248

Current Patients

1-206-306-2800

Physician Line

1-888-987-7782

Clinical Trials

Clinical Trials

Always Researching. Always Advancing.

The medical community continues to conduct research studies on proton therapy. SCCA and other academic medical centers are supporting many ongoing clinical trials to expand our knowledge of the most beneficial applications of proton therapy in treating cancer.

Since proton therapy was approved by the U.S. Food and Drug Administration to treat patients in 1988, the medical community has continued to conduct research on the use of protons in treating different types of cancer through clinical trials. Over the years, many patients have volunteered to take part in these clinical trials to help find improvements in fighting cancer with proton therapy.
With SCCA, our team has made a commitment to participate in clinical trials to further our knowledge of the benefits of proton therapy in many tumor types.

People helping people

Clinical trials are research studies that invite people to participate in the final step in a long process that begins with research in a lab. Each study answers a specific set of scientific questions and explores better ways to prevent, screen for, diagnose or treat a disease. Most treatments used today are the results of past clinical trials. Clinical trials are used even after treatments are approved for use, to help answer additional questions. SCCA Proton Therapy has a registry trial open to all proton therapy patients.

Protocols help us find solutions

For every clinical trial, a protocol, or action plan, is prepared prior to conducting the trial. The protocol describes in detail what will be done in the study, how it will be conducted, and why each part of the study is necessary. Each study has its own rules about who can participate. For instance, some studies need patients with a certain condition, some need healthy people, some need just men or just women, etc.

Your participation can make a difference

Clinical trials are carefully controlled research studies done with patients who volunteer. There are many requirements you must meet to be part of a study. If you qualify, it is up to you whether to take part.
Not all patients are cured with standard therapy, and some standard treatments may have side effects that patients and doctors would prefer to avoid, if possible. So patients may seek help through clinical studies. Patients who participate in studies have the first chance to benefit from treatments that have shown promise in earlier research. They also make an important contribution to medical science by helping doctors learn more about the disease and potential new treatments.

Featured Clinical Trials

Access Breakthrough Treatments. Improve Care to Others.

A critical part of the mission at our partner Seattle Cancer Care Alliance (SCCA) is to bring promising new treatments to patients faster. Patients who participate in clinical studies often have the first chance to benefit from treatment approaches that have shown promise in earlier research.

Proton therapy’s efficacy in treating many types of cancer has been well established, but many questions remain unanswered. Our clinical studies hope to make an important contribution to medical science by helping doctors learn more about how effective proton therapy is in treating cancer when compared with other forms of radiation therapy, and when used in combination with other treatments such as chemotherapy and surgery. We also intend to examine outcomes for patients who receive the higher radiation doses made possible by this precise technology.

Study Principal Investigator Conditions Study ID
Evaluation Tracking Project: A Prospective Chart Review of Patients Treated With Proton Therapy George Laramore, MD Solid Tumors NCT01255748 Learn More
Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial Justin Bekelman, MD Breast Cancer NCT02603341 Learn More
Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma George Laramore, MD CNS: Recurrent Glioblastoma NCT01730950 Learn More
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Lia Halasz, MD CNS: Glioblastoma NCT02179086 Learn More
Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Kurt Jaeckle, MD CNS: Glioma NCT00887146 Learn More
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery Lia Halasz, MD CNS: Meningioma NCT03180268 Learn More
Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery Smith Apisarnthanarax, MD GI: Liver NCT02881554 Learn More
Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer (PARTIQoL) Jing Zeng, MD Prostate Cancer NCT01617161 Learn More
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer (COMPPARE) Nancy Mendenhall, MD Prostate Cancer NCT03561220 Learn More
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC Ramesh Rengan, MD Lung Cancer NCT01993810 Learn More
FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging Jing Zeng, MD Lung Cancer NCT02773238 Learn More
Definitive Re-Irradiation With Proton Beam Radiotherapy for Patients With Recurrent Thoracic Cancers Jing Zeng, MD Lung Cancer NCCT02204761 Learn More
Pediatric Proton Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients treated with Proton Radiation Therapy Ralph Ermoian, MD Childhood Cancers NCT01696721 Learn More
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults Doug Hawkins, MD Childhood: Hodgkin Lymphoma AHOD1331 Learn More
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System Sarah Leary, MD Childhood: Embryonal Tumors NCT00867178 Learn More
Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT) Doug Hawkins, MD Childhood: CNS Germ Cell Tumors NCT01602666 Learn More
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years Amy A Smith, MD Childhood: Ependymoma NCT01096368 Learn More
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-RiskWNT-Driven Medulloblastoma Patients Nicholas Gottardo, MD Childhood: Medulloblastoma ACNS1422 Learn More
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma Rochelle Bagatell, MD Childhood: Neuroblastoma NCT03126916 Learn More
A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma Doug Hawkins, MD Childhood: Ewing Sarcoma NCT01231906 Learn More
Randomized Phase II Trial Evaluating the Additional of the IFG-1R Monocional Antibody Ganitumab to Multiagent Chemotherapy for Patients with Newly Diagnozed Metastatic Ewing Sarcoma Doug Hawkins, MD Childhood: Metastatic Ewing Sarcoma NCT02306161 Learn More
Randomized Phase III Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) Doug Hawkins, MD Childhood: Rhabdomyosarcoma ARST1431 Learn More

Featured Studies

Study Principal Investigators
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial Parker CC, James ND, Brawley CD, et. al. Read Study